BMO Capital analyst Gary Nachman notes a 'good outcome' for Pacira Pharmaceuticals (NASDAQ: PCRX) exparel sales related to expectations ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE